Exploration of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis: a scoping review protocol
暂无分享,去创建一个
[1] P. Molyneaux,et al. Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001–2017 , 2022, ERJ Open Research.
[2] G. Tikellis,et al. Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia , 2021, Respirology.
[3] Y. Inoue,et al. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden , 2021, Respirology.
[4] Jessica Mcfarlin,et al. Palliative Care for the Interstitial Lung Disease Patient a Must and Not Just a Need , 2021, The American journal of hospice & palliative care.
[5] M. Wijsenbeek,et al. Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey , 2021, Frontiers in Medicine.
[6] M. Kreuter,et al. Global incidence and prevalence of idiopathic pulmonary fibrosis , 2021, Respiratory Research.
[7] C. Moor,et al. The Value of the Surprise Question to Predict One-Year Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study , 2021, Respiration.
[8] K. Gibson,et al. Nurse-Led Palliative Care Improves Knowledge and Preparedness in Caregivers of Patients with Idiopathic Pulmonary Fibrosis. , 2021, Annals of the American Thoracic Society.
[9] F. Dobbels,et al. Patients’ and healthcare professionals’ perspectives on the idiopathic pulmonary fibrosis care journey: a qualitative study , 2021, BMC Pulmonary Medicine.
[10] Micah D J Peters,et al. Updated methodological guidance for the conduct of scoping reviews , 2020, JBI evidence synthesis.
[11] E. Bargagli,et al. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study , 2020, Frontiers in Molecular Biosciences.
[12] T. Morita,et al. Palliative care for idiopathic pulmonary fibrosis patients: Pulmonary physicians' view. , 2020, Journal of pain and symptom management.
[13] G. Tikellis,et al. The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review , 2020, European Respiratory Review.
[14] F. Luppi,et al. What patients with Idiopathic Pulmonary Fibrosis and caregivers want - Filling the currents gaps with patient reported outcomes and experience measures. , 2020, The American journal of medicine.
[15] Z. Daniil,et al. Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study , 2020, ERJ Open Research.
[16] AR Tyas,et al. S43 Has introduction of severity criteria improved palliative care provision for patients with idiopathic pulmonary fibrosis? , 2019, Integrative working to improve patient experience in lung disease.
[17] A. Prasse,et al. Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey , 2019, ERJ Open Research.
[18] Zachary Munn,et al. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach , 2018, BMC Medical Research Methodology.
[19] A. Holland,et al. Understanding the patient's experience of care in idiopathic pulmonary fibrosis , 2018, Respirology.
[20] J. McGowan,et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation , 2018, Annals of Internal Medicine.
[21] M. Kreuter,et al. Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views , 2018, Respiration.
[22] R. Kaarteenaho,et al. Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries , 2018, Multidisciplinary Respiratory Medicine.
[23] Sarah Meadows,et al. Understanding the informational needs of patients with IPF and their caregivers: ‘You get diagnosed, and you ask this question right away, what does this mean?’ , 2018, BMJ open quality.
[24] M. Kreuter,et al. Palliative care in interstitial lung disease: living well. , 2017, The Lancet. Respiratory medicine.
[25] A. Russell,et al. Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries , 2017, BMC Pulmonary Medicine.
[26] J. Yorke,et al. Palliative care and interstitial lung disease , 2017, Current opinion in supportive and palliative care.
[27] A. Chetta,et al. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. , 2017, Pulmonary pharmacology & therapeutics.
[28] R. McFadden,et al. Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada , 2017 .
[29] J. Geelhoed,et al. Optimizing quality of life in patients with idiopathic pulmonary fibrosis , 2017, Therapeutic advances in respiratory disease.
[30] H. Hoogsteden,et al. What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany , 2017, ERJ Open Research.
[31] D. Lynch,et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.
[32] J. McGowan,et al. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. , 2016, Journal of clinical epidemiology.
[33] Y. Moodley,et al. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations , 2016, Drugs & Aging.
[34] C. Janson,et al. End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study , 2016, Thorax.
[35] A. Russell,et al. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’ perspectives of the disease and treatment , 2016, BMC Pulmonary Medicine.
[36] A. Nelson,et al. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study , 2015, BMC Pulmonary Medicine.
[37] W. Wuyts,et al. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers , 2015, European Respiratory Journal.
[38] N. Chaudhuri,et al. IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe , 2015, Advances in Therapy.
[39] Augustine S. Lee,et al. The burden of idiopathic pulmonary fibrosis: an unmet public health need. , 2014, Respiratory medicine.
[40] D. Janssen,et al. Palliative care and pulmonary rehabilitation. , 2014, Clinics in chest medicine.
[41] and Quality,et al. Assessing the Accuracy of Google Translate to Allow Data Extraction From Trials Published in Non-English Languages , 2013 .
[42] L. Spencer,et al. Perceptions, experiences and information needs of patients with idiopathic pulmonary fibrosis (IPF): A qualitative study , 2012 .
[43] A. Cohen,et al. Living with idiopathic pulmonary fibrosis , 2011, Chronic respiratory disease.
[44] A. Cohen,et al. Living With Idiopathic Pulmonary Fibrosis (IPF): An In-Depth Qualitative Survey Of European Patients , 2011, ATS 2011.
[45] Takeshi Johkoh,et al. American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .
[46] H. Collard,et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.
[47] G. Oster,et al. Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.
[48] J. Sim,et al. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. , 2005, Physical therapy.
[49] K. Gibson,et al. The palliative care needs of patients with idiopathic pulmonary fibrosis: A qualitative study of patients and family caregivers , 2017, Heart & lung : the journal of critical care.
[50] E. White,et al. Disparities in Lung Transplantation Among Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry , 2022, TP26. TP026 DIAGNOSIS, ASSESSMENT, AND PROGNOSIS OF FIBROTIC ILD.